MARYVILLE, Tenn. – (Sept 17, 2015) – Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The new panels will address Lung, Colon, Melanoma and an unknown primary 8 gene panel with soon to be released Gastrointestinal Stroma, Glioma, Ovarian, Renal and Thyroid solid tumor panels.
Molecular Pathology Laboratory’s experience in system evaluation and validation led to the selection of the QIAGEN® GeneRead™ DNAseq Targeted Human Tumor Actionable Mutations Panel. This panel sequences portions of the BRAF, EGFR, IDH1, IDH2, KIT, KRAS, NRAS and PDGFRA genes and is validated as a Laboratory Developed Assay following MPLN’s Quality Management System. “We chose this particular reagent system because it can be run on any NGS platform, building on our existing molecular diagnostic capabilities and with reliable uptime being extremely important to meet turnaround time expectations of our clients. The panel is also well suited to formalin fixed paraffin embedded specimens with as little as 10ng starting DNA” said Jamie Platt, Vice President Genomic Solutions for MPLN.
MPLN’s Solid Tumor panels targets key regions of 8 genes identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO) as having clinically actionable somatic mutations in solid tumors. Although many genes are somatically mutated during carcinogenesis, few of these mutations have confirmed prognostic or diagnostic importance. Since the key mutations in each gene have been identified through clinical trials, this targeted enrichment panel focuses on only those relevant genomic locations, saving sequencing space for higher throughput or greater sequencing depth to detect variants at lower minor allele frequencies.
The Solid Tumor Panels are ideal for the workup of oncology specimens. The panels maximizes reimbursement by including only those actionable genes identified in clinical guidelines. The variants in genes associated with each disease type are identified using CLCbio, a QIAGEN Company, Cancer Research Workbench informatics solution and the clinical significance of each of those variants are determined and reported using GenomOncology Clinical Workbench. “We chose the GeneomeOncology Clinical Workbench because it utilizes MyCancer Genome with integrated decision support provided by data derived from FDA, ASCO and NCCN.” Commented Jamie Platt.
MPLN will also be making the QIAGEN Human Tumor Actionable Mutations Panel available to Geneuity Clinical Research Services for clinical trial studies as well.
Commenting is turned off for this post.Commenting is not available in this channel entry.